Skip to content

Belgian Lung Function Study

Belgian Lung Function Study: Personalised Longitudinal Lung Function Analysis as a Marker of Disease Progression

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07419555
Acronym
AIRCAST
Enrollment
4000
Registered
2026-02-19
Start date
2026-03-25
Completion date
2029-03-01
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Respiratory Diseases

Keywords

lung function, trajectory, predictions

Brief summary

Currently, it remains unclear how to manage serial lung function measurements in a clinical setting. The investigators aimed to tackle this problem by developing a machine learning (ML) model that can accurately predict population and individual lung function trajectories. These predictions would enable the investigators to identify positive or negative deviations, thereby revealing unexpected disease patterns. A prospective validation is needed that includes data on mortality, hospitalisations, emergency-room visits and patient-reported outcomes. Within this study, the goal is to validate the ML model with the data collected from this observational study.

Detailed description

The objective of this study is to explore the clinical value of models predicting longitudinal lung function patterns in individuals with chronic respiratory diseases across Belgium. 1. The investigators will assess the accuracy of individualised lung function prediction models in a multicentre lung function dataset with prospective clinical and lung function follow-up. 2. The investigators will evaluate important health outcomes, step-up in care, patient-reported outcomes in individuals identified with an expected and unexpected observed trajectory as compared to the predicted population and individualised trajectory. The hypothesis is that patients with an unexpected decline in lung function will have worse health outcomes, such as a higher mortality rate and more hospitalisations, compared to patients with an expected lung function pattern. The investigators hypothesise to observe better health outcomes and lower mortality rates in patients with an unexpectedly positive lung function evolution compared to patients with an expected negative lung function pattern. Individuals will be recruited from 4 Belgian Hospitals (UZ Leuven, UZ Antwerpen, AZ Delta, ZOL Genk). Based on the annual rate of pulmonary function testing in these hospitals, a sample size of 1.000 participants per centre is anticipated within one year of inclusions, resulting in a total sample size of 4.000 patients. All available historical lung function data of included individuals will be retrieved from the individuals medical file. Additionally, the individual will be prospectively followed for 2 years where all lung function data will be collected.

Interventions

None listed

Sponsors

KU Leuven
Lead SponsorOTHER
AZ Delta
CollaboratorOTHER
University Hospital, Antwerp
CollaboratorOTHER
Ziekenhuis Oost-Limburg
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Above 18 years old * Diagnosed with a chronic respiratory disease and followed up in one of the participating Belgian hospitals * Performed a complete lung function test (spirometry, body plethysmography and diffusion capacity) at baseline * Have at least 3 historical spirometry measurements over a minimal time window of 2 years prior to inclusion * Planned routine follow-up within standard clinical care in one of the participating hospitals

Exclusion criteria

* Patients who have had a lung transplantation * Patients not being able to give consent to participate

Design outcomes

Primary

MeasureTime frameDescription
Accuracy of lung function predictions (FEV1)at 1 and 2-year follow-upProportion of correct and incorrect FEV1 predictions compared to the observed measure

Secondary

MeasureTime frameDescription
Differences in clinical outcomes between correct and incorrect lung function predictions (FEV1)at 1 and 2-year follow-upDifferences between patients with correct and incorrect individual lung function predictions for FEV1 on clinical endpoints (such as mortality, hospitalisations, frailty, health status and step-up in care
Accuracy of lung function predictionsat 1 and 2-year follow-upProportion of correct and incorrect lung function predictions (FVC, TLC, RV/TLC, DLCO) compared to the observed measure
Differences in clinical outcomes between correct and incorrect lung function predictionsat 1 and 2-year follow-upDifferences between patients with correct and incorrect individual lung function predictions for FVC, TLC, RV/TLC, DLCO on clinical endpoints (such as mortality, hospitalisations, frailty, health status and step-up in care)
Identifying the minimal needed to make predictionsafter 2 yearsMinimal number of tests/length of follow-up required for optimal predictions
Performance of ML-based predictions compared to linear regression analysisat 1 and 2-year follow-upComparison of the ML-based predictions for individual and population lung function changes with predictions based on linear regression on individual historical data
Overall description of populationbaseline, 1 and 2-year follow-upSociodemographic information, health status, comorbidities, frailty, disease labels, interventions and prognosis of individuals with a chronic respiratory disease

Countries

Belgium

Contacts

CONTACTMarieke Wuyts
marieke.wuyts@kuleuven.be016 34 31 59
PRINCIPAL_INVESTIGATORWim Janssens

UZ/KU Leuven

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026